Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.57M | -13.37M | -11.61M | -11.45M | -12.85M |
| Total Depreciation and Amortization | 7.00K | 6.00K | 5.00K | 5.00K | 11.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.69M | -1.79M | -2.53M | 107.00K | 1.79M |
| Change in Net Operating Assets | 342.00K | 1.11M | 2.31M | 1.65M | -1.28M |
| Cash from Operations | -14.90M | -14.04M | -11.82M | -9.69M | -12.33M |
| Capital Expenditure | -- | -22.00K | -22.00K | -22.00K | -22.00K |
| Sale of Property, Plant, and Equipment | -- | 1.00K | 1.00K | 111.00K | 111.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 6.57M | 0.00 | 0.00 | 15.00K |
| Cash from Investing | 0.00 | 6.55M | -21.00K | 89.00K | 104.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.00M | 162.00K | 162.00K | 7.52M | 7.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -967.00K | -162.00K | -162.00K | -162.00K | -162.00K |
| Cash from Financing | 14.03M | 0.00 | 0.00 | 7.36M | 7.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | 2.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -872.00K | -7.49M | -11.84M | -2.24M | -4.87M |